Advanced Accelerator Applications (“AAA”) announced that it had successfully completed a capital increase of €41 million.
This capital increase will help fund expansion plans and finance clinical trials of its promisingportfolio of Molecular Nuclear Medicine diagnostic and therapeutic products.
Download the press release (17 February 2014) >>